BioSpace News Archive

Nemaura Medical, Inc., a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announced progress with the German regulatory authority to achieve reimbursement for its sugarBEAT® device.

Company intends to develop and extend its diverse pipeline of therapies for cancer and immune diseases, beginning with four entities

Vincerx Pharma, Inc., announced the completion of its redemption event with respect to its outstanding public warrants.

– In collaboration, Aeterna and The University of Sheffield, UK have selected the development candidate AEZS-150, a parathyroid hormone (PTH) fusion polypeptide to start the formal preclinical development for potentially enabling the first in human clinical study. – AEZS-150 has the potential to become a new therapeutic treatment option of primary hypoparathyroidism.

Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, today announced that the U.S. Food and Drug Administration (FDA) has approved a single 1000 mg dose option of Injectafer®

The Aplastic Anemia and MDS International Foundation (AAMDSIF) and the National Organization for Rare Disorders (NORD®) today launched the largest-ever study to research Paroxysmal Nocturnal Hemoglobinuria (PNH), a rare bone marrow failure disease

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results for the first quarter ended March 31, 2021 and provided a corporate update.

BioIntelliSense, Inc., a continuous health monitoring and clinical intelligence company, today announced the BioButton™ was named the Best New Monitoring Solution in the fifth annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough,

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today reported business highlights and financial results for the first quarter ended March 31, 2021 .

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, announced that it has entered into an amendment to its existing loan and security agreement with Oxford Finance LLC and Silicon Valley Bank.